Exercise-induced asthma in children

Pediatric Drugs

Volumn 4, Issue 4, 2002, Pages 267-278

  Massie, John ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; FUROSEMIDE; INDOMETACIN; LONG ACTING DRUG; MONTELUKAST; NEDOCROMIL SODIUM; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE DERIVATIVE; ZAFIRLUKAST; ZILEUTON;

ANXIETY NEUROSIS; COUGHING; DRUG TOLERANCE; DRY POWDER; DYSPNEA; EXERCISE INDUCED ASTHMA; HUMAN; METERED DOSE INHALER; PATHOGENESIS; PHYSICAL ACTIVITY; POWDER INHALER; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; TREMOR;

EID: 0036256930     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204040-00006     Document Type: Review

References (107)

1. Prevalence of possible undiagnosed asthma and associated morbidity among urban school children
2. An exercise challenge for epidemiological studies of childhood asthma: Validity and repeatability
3. Bronchial responsiveness to exercise in a random sample of 494 children and adolescents from Copenhagen
4. Airways responsiveness in a population sample of adults and children
5. Keeping children with exercise-induced asthma active
6. Exercise-induced asthma: Update on pathophysiology, clinical diagnosis, and treatment
7. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children
8. Increased bronchial responsiveness to exercise and histamine after allergen challenge in children with asthma
9. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma
10. Characterization of the late response in exercise-induced asthma
11. Factors predisposing to exercise-induced late asthmatic responses
12. Effect of exercise on nonspecific airway reactivity in asthmatics
13. Exercise-induced bronchoconstriction does not cause eosinophilic airway inflammation or airway hyperresponsiveness in subjects with asthma
14. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults
15. Is there a unifying hypothesis for exercise-induced asthma?
16. The mechanism of exercise-induced asthma is
17. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma
18. The protective effect of nedocromil sodium and other drugs on airway narrowing provoked by hyperosmolar stimuli: A role for the airway epithelium?
19. Thermally induced asthma and airway drying
20. Role of respiratory heat exchange in production of exercise-induced asthma
21. Heterogeneity of mechanisms in exercise induced asthma
22. The effect of an inhaled corticosteroid (budesonide) on exercise-induced asthma in children
23. Exercise performance in the asthmatic
24. Exercise-induced asthma
25. Section of Diseases of the Chest. Exercise and the asthmatic child
26. Albuterol: An adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use
27. Clinical pharmacokinetics of beta-agonists
28. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children
29. Spacing devices and metered-dose inhalers in childhood asthma
30. Influence of inspiratory flow rate upon the effect of a turbuhaler
31. No protection by oral terbutaline against exercise-induced asthma in children: A dose-response study
32. The British guidelines on asthma management 1995: Review and position statement
33. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature
34. Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists
35. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro
36. The pharmacology of salmeterol
37. The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children
38. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol
39. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma
40. Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: A double-blind cross-over study versus salbutamol
41. Formoterol and salbutamol metered aerosols: Comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma
42. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists
43. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children
44. Flow-dependent effect of formoterol dry-powder inhaled from the aerolizer
45. Prevention of exercise induced asthma by inhaled salmeterol xinafoate
46. Overnight protection by inhaled salmeterol on exercise-induced asthma in children
47. Salmeterol in exercise-induced bronchoconstriction in asthmatic children: Comparison of two doses
48. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children
49. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment
50. Formoterol: An update of its pharmacological properties and therapeutic efficacy in the management of asthma
51. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects
52. Salmeterol: A review of its pharmacological properties and clinical efficacy in the management of children with asthma
53. Rapid onset of tolerance to the bronchoprotective effect of salmeterol
54. Inhaled disodium cromoglycate (DSCG) as maintenace therapy in children with asthma: A systematic review
55. Nedocromil sodium in the treatment of exercise-induced asthma: A meta-analysis
56. Cromolyn versus nedocromil: Duration of action in exercise-induced asthma in children
57. Sodium cromoglycate as a pressurised aerosol (vicrom) in exercise-induced asthma
58. The effect of sodium cromoglycate delivered by spinhaler and by pressurized aerosol on exercise-induced asthma in children
59. Dose-response study of sodium cromoglycate in exercise-induced asthma
60. The dose-duration effect of sodium cromoglycate in exercise-induced asthma
61. Sodium cromoglycate delivered by pressurized aerosol in the treatment of asthma
62. Comparison of sodium cromoglycate pressurized aerosol and powder in the treatment of asthma
63. Dose-response effect of sodium cromoglycate pressurised aerosol in exercise induced asthma
64. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma (EIA) in adults
65. Nedocromil sodium versus cromoglycate for the pre-treatment of exercise induced bronchoconstriction in asthma
66. Time course of effect of disodium cromoglycate on exercise-induced asthma
67. Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise-induced asthma
68. Role of leukotrienes in exercise-induced asthma: Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist
69. Antileukotriene drugs in childhood asthma: What is their place in therapy?
70. Asthma in children: Optimising therapy
71. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma
72. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial
73. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial
74. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial
75. Leukotriene receptor antagonists: Efficacy and safety in children with asthma
76. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
77. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma
78. Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma
79. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children
80. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction
81. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: A randomized, double-blind trial
82. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxygenase inhibitor
83. Montelukast dose selection in 6- to 14-year-olds: Comparison of single-dose pharmacokinetics in children and adults
84. Clinical pharmacology of drugs used for asthma
85. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze
86. Eosinophils in exercise-induced asthma
87. Severity of exercise-induced bronchoconstriction is related to airway eosinophilic inflammation in patients with asthma
88. Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma
89. Budesonide treatment of moderate and severe asthma in children: A dose-response study
90. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids
91. Low-dose budesonide improves exercise-induced bronchospasm in school children
92. Effects of enprofylline and theophylline on exercise-induced asthma
93. The place of physical exercise and bronchodilator drugs in the assessment of the asthmatic child
94. Inhibition of exercise-induced asthma by theophylline
95. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin
96. Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma
97. The effect of calcium antagonist, nifedipine in exercise-induced asthma
98. Calcium antagonists in exercise-induced asthma
99. Prevention of exercise-induced bronchoconstriction by inhaled frusemide
100. Exercise-induced asthma
101. The refractory period after exercise-induced asthma: Its duration and relation to the severity of exercise
102. Protective effects of repeated short sprints in exercise-induced asthma
103. The effect of prolonged submaximal warm-up exercise on exercise-induced asthma
104. The economic aspects of drug delivery in asthma
105. Overview of delivery system issues in pediatric asthma